During the same period last year, the company posted ($0.99) EPS. Blueprint Medicines’s quarterly revenue was down 63.8% compared to the same quarter last year. Blueprint Medicines had a negative net margin of 273.24% and a negative return on equity of 80.09%. The firm had revenue of $38.78 million for the quarter, compared to analyst estimates of $33.52 million. The biotechnology company reported ($2.65) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.73) by $0.08. Get Blueprint Medicines alerts:īlueprint Medicines ( NASDAQ:BPMC – Get Rating) last issued its quarterly earnings results on Thursday, February 16th. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $76.28. Two research analysts have rated the stock with a sell rating, six have given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Finally, Wedbush reduced their target price on shares of Blueprint Medicines from $120.00 to $106.00 and set an “outperform” rating for the company in a report on Wednesday, November 2nd. Wells Fargo & Company raised shares of Blueprint Medicines from an “underweight” rating to an “equal weight” rating and set a $41.00 price target for the company in a research report on Monday, January 2nd. Needham & Company LLC decreased their price objective on shares of Blueprint Medicines from $60.00 to $57.00 and set a “buy” rating for the company in a research report on Friday, February 17th. Morgan Stanley dropped their price target on shares of Blueprint Medicines from $75.00 to $50.00 and set an “equal weight” rating for the company in a research note on Friday, January 27th. SVB Leerink cut their price target on shares of Blueprint Medicines from $57.00 to $52.00 and set a “market perform” rating for the company in a report on Wednesday, November 2nd. Blueprint Medicines ( NASDAQ:BPMC – Get Rating) was downgraded by stock analysts at from a “hold” rating to a “sell” rating in a research note issued to investors on Monday.īPMC has been the subject of a number of other research reports.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |